about
Alprazolam for essential tremorAlprazolam for essential tremorZonisamide for essential tremorTopiramate for essential tremorPregabalin for essential tremorCOMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson's disease (PD): relevance for motor and non-motor featuresA Personalized Approach in Progressive Multiple Sclerosis: The Current Status of Disease Modifying Therapies (DMTs) and Future PerspectivesTwo novel SCN1A missense mutations in generalized epilepsy with febrile seizures plusMutations in the mitochondrial GTPase mitofusin 2 cause Charcot-Marie-Tooth neuropathy type 2AA Novel Mutation in the Notch3 Gene in an Italian Family With Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and LeukoencephalopathyTemporal lobe epilepsy as a unique manifestation of multiple sclerosis.MR imaging of middle cerebellar peduncle width: differentiation of multiple system atrophy from Parkinson disease.Multiple sclerosis and CCSVI: a population-based case control study.Treatment of essential tremor: a systematic review of evidence and recommendations from the Italian Movement Disorders Association.Obsessive compulsive personality disorder and Parkinson's disease.Report of two never treated adult sisters with aromatic L-amino Acid decarboxylase deficiency: a portrait of the natural history of the disease or an expanding phenotype?Multiple Sclerosis in the Mount Etna region: possible role of volcanogenic trace elements.Lesion load may predict long-term cognitive dysfunction in multiple sclerosis patients.Prevalence and Incidence of Epilepsy Associated with Convulsive Seizures in Rural Bolivia. A Global Campaign against Epilepsy Project.CSF N-glycoproteomics for early diagnosis in Alzheimer's disease.Clinical and radiologic rebound after discontinuation of natalizumab therapy in a highly active multiple sclerosis patient was not halted by dimethyl-fumarate: a case report.Side effects induced by the acute levodopa challenge in Parkinson's Disease and atypical parkinsonisms.MR imaging index for differentiation of progressive supranuclear palsy from Parkinson disease and the Parkinson variant of multiple system atrophy.The role of the long-duration response to levodopa in Parkinson's disease.Selegiline: a reappraisal of its role in Parkinson disease.Glycomics of pediatric and adulthood diseases of the central nervous system.Scales for hyperkinetic disorders: A systematic review.Zonisamide for essential tremor.Vascular parkinsonism or idiopathic NPH? New insights from CSF pressure analysis.Head trauma and Parkinson's disease: results from an Italian case-control study.Iron and Parkinson's disease: A systematic review and meta-analysis.When the word doesn't come out: A synthetic overview of dysarthria.Migraine causes retinal and choroidal structural changes: evaluation with ocular coherence tomography.Magnetic resonance parkinsonism index in progressive supranuclear palsy and vascular parkinsonism.Magnetic fields exposure from high-voltage power lines and risk of amyotrophic lateral sclerosis in two Italian populations.Residential facilities for older people in Italy: a five-region survey.Risk factors in multiple sclerosis: a population-based case-control study in Sicily. Background and methods.Clinical phenotype and risk of levodopa-induced dyskinesia in Parkinson's disease.Pisa syndrome in Parkinson disease: An observational multicenter Italian study.PACAP and PAC1R are differentially expressed in motor cortex of amyotrophic lateral sclerosis patients and support survival of iPSC-derived motor neurons.
P50
Q24187196-169F85DC-C0C6-474E-A1B8-A8273B0C488EQ24201430-FB38E8F6-235F-4BB4-BEA9-EBE2666D095BQ24201497-C282288C-BBC8-4888-BEB1-0F63195DDA10Q24201606-C5593B31-9651-4EC8-B928-BCA59F254DE2Q24203614-5784C967-4129-4C34-B3FD-E9AE6A6F347FQ24644555-2B4F7B80-540F-44B5-A1D9-A9E3C074239AQ28068709-36AEDEDE-1B6B-4C57-8675-5CD90A42F1C1Q28201856-1C84BAA2-4B8F-4434-916B-75295511D3D8Q29616547-36CD8AD3-DE76-42D4-8272-6E582D6CF5D9Q30052580-51223FEB-62B2-4B44-949F-C5E3973ABE7EQ30821435-79E3361E-C6E0-47A2-94F2-FCE5B27D8005Q31041578-FAB02996-B4FF-49DC-8A21-E597F0D42365Q34368835-53C51C5A-14BD-4C49-9346-695DA8B41C74Q34376919-D6C23CCE-CD40-43C1-9CA1-4855AF89C6A7Q34566550-8ED8D3FC-D306-49D5-A96F-A105167F0910Q34734658-338D1F2A-6EF2-49EA-AEB9-58995D8F941CQ35069359-3875E1F6-A149-486E-9990-4252AD203CBEQ35224690-07A69C82-CFC4-45F4-B6FE-1BEAACE9D8C6Q35795338-4C976FF6-6B21-436B-912D-6E41FA9CEA4FQ35802846-805A9855-63BE-4BAC-BB3E-85A58D76D69FQ35862875-E42AB259-E4A2-4181-B844-78CE2D4C05E0Q36282655-59F414E6-ABC1-4CDA-BC2E-F9430A7D7804Q36996943-E2F5154D-1C6C-4382-A7C0-5DC9C8311774Q37809796-6D02389F-A165-4581-B293-A3A38FF032B5Q38010624-C2A39D2D-AA6C-4E10-800E-A0DCFAD0461AQ38027682-BC425B99-ACF7-4095-9CBC-A9557E4054CCQ38597216-4FA336BD-F572-400E-A37D-9AAB142C892DQ38610647-643D2A06-2219-4CAD-AF19-9D46F84E93A1Q38613052-C531CDDE-985F-44D5-A23F-3492EF2EC38AQ38658595-0AA6842F-7A18-4F88-8BE6-100E5A2FE1B2Q38879419-EBA5E8DA-3357-4AC2-AE29-456F835559F4Q38960905-25BE9275-ED4C-46DA-B696-1AD694963B75Q39061359-70D09DDD-3A12-4613-8B50-D711A91487A2Q40049267-1D0ABFDC-D310-4F59-BCE6-8CE95A5E454FQ40177968-9FB6C3D5-BABF-4E46-AF01-800E650848E4Q40221550-EF1A67B2-3413-40A2-9662-505571C914C8Q40637426-E66113A6-BFAF-4829-9579-493923E0A14BQ40860918-DB0DC589-85F8-47CE-A16E-104A837489EBQ41194904-D0E88529-B54D-47DB-9434-C8D4CD9029EFQ42691548-A0E04C2F-DBFF-4199-8CDE-A54350CA1533
P50
name
Mario Zappia
@ast
Mario Zappia
@en
Mario Zappia
@es
Mario Zappia
@nl
type
label
Mario Zappia
@ast
Mario Zappia
@en
Mario Zappia
@es
Mario Zappia
@nl
prefLabel
Mario Zappia
@ast
Mario Zappia
@en
Mario Zappia
@es
Mario Zappia
@nl